This project focuses on the development of a rapid antigen identification platform, with the aim of accelerating next-generation mRNA vaccine development and enabling faster responses to emerging infectious diseases, an urgent need that remains highly relevant in the post-COVID era.
As part of this initiative, NovoArc contributes its lipid-based formulation technology to advance innovative solutions for efficient mRNA vaccine delivery.






